News

  • 12 August 2014

    JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, today announced that cardiovascular medical device industry veteran Stefan Schreck, Ph.D. has been named the Company’s new chief technology officer, effective immediately.

  • 7 July 2014

    JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, today announced that medical device industry veteran David J. Drachman has been named the Company’s new chief executive officer, effective immediately.

  • 27 June 2014

    InDex Pharmaceuticals today reported top-line results from the double blind, placebo-controlled clinical study COLLECT. The aim of the COLLECT study was to investigate the therapeutic potential of the Toll-like receptor 9 agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis.

  • 4 June 2014

    JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has successfully completed the first implantation of its second-generation transapical JenaValve TAVI system in Sweden.

  • 27 May 2014

    Sonendo®, Inc., the developer of a revolutionary technology for the endodontic marketplace, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the second generation of its Multisonic Ultracleaning System for root canal therapy. The system is designed to be a minimally-invasive, disruptive technology that utilizes multiple wavelengths of sound to clean the entire root canal system simultaneously.